fashion -WSS

fashion

author：hotspot 2025-09-29 19:57:40 - browse：94

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Americans' trust in science, scientist continues decline: Report

WSS

AI models in health care face new federal disclosure requirements

The Karikó problem: Lessons for funding basic research

What causes an itch? Researchers may have solved the mystery

FDA approves world's first CRISPR

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Nobel honors Karikó and Weissman's enduring partnership

knowledge

fashion

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

IVG is promising — but it won’t replace IVF quite yet

Activists slam private health insurers over coverage restrictions

Flu, Covid vaccination rates decline, new survey data show

Affirmative action in medical school literally saved lives

Stop Congress from blocking public access to science

Virginia high school admissions case could be legal follow

Will an HIV vaccine ever be a reality?

In Memoriam: Notable people who died in 2023

Why sickle cell disease is getting the first CRISPR treatment

hotspot

The Karikó problem: Lessons for funding basic research

Congenital heart disease patients face new threat of heart failure

Flu, Covid vaccination rates decline, new survey data show

The Karikó problem: Lessons for funding basic research

In diabetes hearing, Sanders takes on a new foe: food makers

Nobel honors Karikó and Weissman's enduring partnership

explore

hotspot

focus

focus